Reference 33 - Acute respiratory distress syndrome after the use of gadolinium contrast agent.
NonrulemakingSupporting & Related MaterialFDA-2026-P-6737-0035
Document
Details
The document's own metadata, straight from regulations.gov.
- Posted
- Jun 15, 2026
- Agency
- Food and Drug Administration (FDA)